HERON THERAPEUTICS INC (HRTX)
Health Care · Specialty injectable pharmaceuticals for acute care and oncology supportive care · NASDAQ
A commercial-stage biotech company bringing specialized injectable medicines to acute care and oncology settings, with a focus on non-opioid pain management and prevention of nausea in surgical and chemotherapy patients.
What HERON THERAPEUTICS INC does
Heron Therapeutics is a commercial-stage biotechnology company developing and commercializing therapeutic innovations for acute care and oncology patients. The company's portfolio includes ZYNRELEF (bupivacaine and meloxicam extended-release), a dual-acting local anesthetic for postsurgical pain; APONVIE (aprepitant injectable), an IV formulation for postoperative nausea and vomiting prevention; CINVANTI (aprepitant injectable), an NK1 receptor antagonist for chemotherapy-induced nausea and vomiting; and SUSTOL (granisetron extended-release injection). Heron's products leverage proprietary extended-release and formulation technologies to improve patient outcomes and reduce opioid use in surgical and cancer care settings.
Themes: ["Non-opioid pain management","Postoperative pain control / acute care","Postoperative nausea and vomiting (PONV)","Chemotherapy-induced nausea and vomiting (CINV)","Extended-release injectable formulations","Oncology supportive care"]
Fundamentals
- Price$0.43 as of 2026-07-09 close
- Market cap$84M as of 2026-07-10
- 1-year return-80.8% as of 2026-07-09 close
- Net margin-20.5% as of 2026-07-10
- Gross margin+71.1% as of 2026-07-10
- ROE-223.4% as of 2026-07-10
- Debt / equity15.50 as of 2026-07-10
- Revenue growth (YoY)+1.5% as of 2026-07-10
- Beta1.70 as of 2026-07-10
Key risks (from latest filing)
[]
Competitors & peers
- Merck (MRK) - EMEND IV (fosaprepitant) for CINV
- Fresenius Kabi - generic and branded injectable antiemetics
- Baxter (now Baxter International) - regional anesthetics and injectable medications
- Hospira (now Pfizer) - injectable pain and antiemetic products
- Traditional local anesthetics (bupivacaine solutions)
- Conventional 5-HT3 receptor antagonists (ondansetron, granisetron)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.